Boehringer Ingelheim & Eli Lilly Report Results of Jardiance (empagliflozin) in P-III (EMPULSE) Trial for Acute Heart Failure
Shots:
- The P-III (EMPULSE) trial evaluate Jardiance (10mg, qd) vs PBO in 530 hospitalized patients with acute HF
- The results showed that patients experience a clinical benefit of 36% @ 90 days. In an exploratory 2EPs, improvement in KCCQ-TSS from baseline to 90 days, overall clinical benefit was consistent in adults with new or existing HF, with/out diabetes & HFrEF or HFpEF
- The safety results were consistent with the safety profile of Jardiance, ARF rates (7.7% vs 12.1%), similar low incidence of hypoglycemia (1.9% vs 1.5%), volume depletion rates (12.7% vs 10.2%). The therapy has been approved in the US to reduce the risk of CV death & hospitalization for HF, based on (EMPEROR-Preserved) trial
Ref: Boehringer | Image: Boehringer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
